In summary, these findings add significant and novel mechanistic insight into the potential role of HGF/MET signaling in mediating resistance to BRAF and MEK inhibitors and support the clinical evaluation of MET kinase inhibitors and HGF-neutralizing antibodies in melanoma. The gene discussed is MET; the disease is melanoma.